Fourman, Lindsay T.
Stanley, Takara L.
Billingsley, James M.
Sui, Shannan J. Ho
Feldpausch, Meghan N.
Boutin, Autumn
Zheng, Isabel
McClure, Colin M.
Corey, Kathleen E.
Torriani, Martin
Kleiner, David E.
Hadigan, Colleen M.
Chung, Raymond T.
Grinspoon, Steven K.
Funding for this research was provided by:
National Institutes of Health (P30DK040561, P30DK040561, P30AI060354, P30AI060354, U01AI115711, R01DK108370, P30DK040561)
National Cancer Institute
Massachusetts General Hospital
Article History
Received: 1 March 2021
Accepted: 29 April 2021
First Online: 18 May 2021
Competing interests
: L.T.F. has served as a consultant for Theratechnologies, Inc. T.L.S. has served as a consultant for Theratechnologies, and reports research funding from Novo Nordisk, Inc. J.M.B. and S.J.H.S. report research funding from Boehringer Ingelheim. S.J.H.S. also reports research funding from AstraZeneca. K.E.C. reports research funding from Boehringer Ingelheim and has served as a consultant to Novo Nordisk, Inc, and Bristol Myers Squibb. R.T.C. reports research funding from Abbvie, Gilead, Merck, Bristol Myers Squibb, Boehringer Ingelheim, Janssen, and Roche. S.K.G. has served as a consultant (personal) and currently serves as a consultant through an Institutional Consulting Agreement with Theratechnologies. The Mass General Hospital has a royalty and license agreement with Theratechnologies for Tesamorelin. Dr. Grinspoon is the inventor on a patent for GHRH or Analogues Thereof For Use in Treatment of Hepatic Disease (application 16832128). M.N.F., A.B., I.Z., C.M.M., M.T., D.E.K., and C.M.H. report no conflicts of interest.